Communiqués Orexo AB

Actions

Marché Fermé - Nasdaq Stockholm 18:00:00 28/08/2026			Varia. 5j.	Varia. 1 janv.
13,38 ^SEK	+2,14 %		-3,46 %	-55,55 %

25/08	Neuf actions ont atteint aujourd'hui un nouveau plus bas sur 52 semaines à la Bourse de Stockholm	FW
24/08	Dix actions ont atteint aujourd'hui un nouveau plus bas sur 52 semaines à la Bourse de Stockholm	FW

17/07	Orexo: Weak Q2, with potential H2 catalysts nearing – Q2 review	AQ
16/07	Orexo : Audiocast (engelska)	PU
16/07	Orexo Q2 2026 Interim Report	AQ
09/06	Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships	AQ
19/05	Orexo: Promising early-stage data	AQ
19/05	Orexo announces positive outcome from an in-vivo study of OX390	AQ
07/05	Report from Orexo AB’s annual general meeting May 7 2026	AQ
29/04	Orexo: Better visibility, few near-term catalysts – Q1 review	AQ
28/04	Orexo : Earnings Call Q1 2026 (engelska)	PU
28/04	Orexo : Earnings Call Q1 2026	PU
28/04	Orexo : Q1 2026 Interim Report MASTER	PU
28/04	Orexo : Q1 2026 Interim Report 2026	PU
28/04	Orexo : Audiocast	PU
28/04	Orexo Q1 2026 Interim Report	AQ
21/04	Invitation to presentation of Orexo´s Q1 2026 Interim Report	AQ
31/03	Number of shares and votes in Orexo	AQ
30/03	Notice of Annual General Meeting of Orexo	AQ
27/03	Orexo : Sustainability Report 2025	PU
27/03	Orexo publishes Annual Report for 2025	AQ
24/03	Orexo: Key takeaways from R&D Day	AQ
24/03	Orexo R&D Day - Building global leadership in amorphous drug delivery	AQ
06/03	Invitation & Agenda: Orexo R&D Day on March 24	AQ
06/03	Orexo: Management changes no major surprise	AQ
06/03	Orexo changes the organizational structure and management team to increase focus on development of new products	AQ
04/03	Orexo calls for early redemption of its outstanding senior secured social bonds 2024/2028	AQ